Pfizer says experimental breast cancer drug cuts risk of disease worsening in mid-stage trial

March 17 (Reuters) – Pfizer said on Tuesday its experimental combination reduced the risk of disease progression or death by 40% ​in patients with breast cancer.

Here are some ‌details:

(Reporting by Sahil Pandey in Bengaluru; Editing by Krishna ​Chandra Eluri)